We continue to publish exclusive content taken from the Talent Alumni Review Magazine. As well as this interview, you can also find the interview that has already been published with Joan-Jordi Arnó, former student of the Executive MBA and Vice-Chairman of the Simply programme at Schneider Electric.
As explained by Agustín Capandeguy, the director supervising the development of the Talent Alumni Review, the magazine will be published twice a year and is available at all of the School’s offices. Moreover, you can also download the online version of the magazine by clicking here.
On this occasion, we would like to introduce you to Javier Lozano, who has a Bachelor Degree in Biochemistry and a Master in Molecular Biology, both from the UAB. At EAE Business School, he took the Executive MBA, “which marked a turning point” in his career. His training at the School has enabled him to take on different roles in three of the most important departments of a multinational pharmaceutical company, or in his own words Medical, Marketing and Sales.
Javier Lozano has held the position of Medical Scientific Liaison, Sales, Marketing and Medicine Advisor and Strategist Consultant at Novartis. Since September, he has been working as the Medical Science Manager at Swedish Orphan Biovitrum.
For 13 years in a row, Novartis has appeared on the list of Great Places to Work. What factors have contributed towards his company taking the top spot?
In my opinion, it is the culmination of the work carried out over nearly fifteen years. Success in this respect is based on the perception that the employees have of the HR practices and policies of the company that they work in. Therefore, factors such as work-life balance, equality of treatment of workers and identifying with the company’s values are crucial.
Work-life balance is an extremely important issue. How is it managed?
As far as I understand, the company offers its associates a broad range of measures that enable them to organize their work time, such as flexible hours, telework, etc., as well as other measures in relation to family and responsibilities and needs.
As well as being a Strategist Consultant, you also hold the role of Scientific Liaison. How would you describe this position?
Against the backdrop of change that the health industry in currently undergoing, the MSL is a key figure. Both from a strategic perspective, with the shift towards transparency that is taking place in the sector, and from an operation viewpoint, the MSL is at the inter-relational nerve centre between the healthcare system and the industry. The numbers speak for themselves, as shown by the huge number of companies that have incorporated this new role as part of their workforce. As such, the MSL is a role focused on convergence and change, on future and progress. To put it simply, it is an exciting environment to be working in.
You are just embarking on a new professional stage as the Medical Science Manager at Swedish Orphan Biovitrum, specializing in research into rare diseases. What does this change mean for you?
It is a unique opportunity to contribute towards improving the lives of patients that suffer less common diseases in a company founded expressly with the vocation to provide help and service to this group.
Do you believe that pharmaceutical companies should conduct R&D together to achieve true progress?
True progress requires advances that put technology within the reach of the entire society, and this cannot be achieved with an insular approach. Joint R&D is increasingly seen as a solution and it is put into practice among the pharmaceutical companies, but to a limited extent. Examples include the digitization of medicine and the shift in the healthcare industry towards an approach based on health results. However, for a pharmaceutical technology to be within everybody’s reach, there has to be a convergence of the objectives of all of the parties involved, the health industry and the healthcare system.